) vaccines division, Sanofi Pasteur, announced that a phase III
efficacy study on its dengue vaccine candidate has met the primary
The randomized, observer-blind, placebo-controlled, multi-center
phase III study enrolled 20,875 children aged between 9 and 16
years in Latin American and Caribbean countries (including Brazil,
Colombia, Mexico, Honduras and Puerto Rico). The study compared the
use of three injections of the dengue vaccine and placebo at
intervals of six months.
Data from the study revealed that the use of the dengue vaccine
resulted in a 60.8% reduction in dengue disease cases.
Additionally, a clinically important reduction in the risk of
hospitalization due to dengue (80.3%) was observed. The dengue
vaccine candidate also demonstrated efficacy in reducing dengue
hemorrhagic fever (the severe form of dengue), which is in line
with the data from another pivotal phase III study (Asia),
announced earlier this year.
According to the World Health Organization (WHO), approximately 100
million people suffer from dengue infection each year. The WHO has
targeted to reduce morbidity and mortality by 25% and 50% by 2020,
However, there is no specific treatment currently available for
this disease, indicating an unmet market need. Sanofi aims to tap
this market with its dengue vaccine candidate.
We note that Sanofi possesses one of the world's leading vaccine
operations with total sales of €1.3 billion in the first half of
2014. The company's portfolio includes pediatric vaccines,
influenza vaccines, adult and adolescent booster vaccines,
meningitis vaccines, and travel and endemic vaccines. Sanofi also
has a strong position in both seasonal and pre-pandemic influenza
vaccines. Sanofi continues to expand its vaccine business. We
expect a significant ramp in vaccine sales over the next several
Sanofi carries a Zacks Rank #3 (Hold). Some better-ranked stocks in
the health care sector include Amgen Inc. (
), Allergan Inc. (
) and Gilead Sciences Inc. (
). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
SANOFI-AVENTIS (SNY): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
AMGEN INC (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.